AIM
RXRX icon

ARK Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

ARK Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152M Buy
41,337,632
+1,124,863
+3% +$3.74M 0.98% 31
2026
Q1 		$123M Buy
40,212,769
+2,895,913
+8% +$11.2M 0.96% 36
2025
Q4 		$153M Buy
37,316,856
+3,771,357
+11% +$18.7M 1.01% 33
2025
Q3 		$164M Buy
33,545,499
+556,868
+2% +$2.92M 0.97% 27
2025
Q2 		$167M Sell
32,988,631
-1,826,871
-5% -$8.97M 1.22% 21
2025
Q1 		$184M Buy
34,815,502
+2,469,104
+8% +$18M 1.84% 17
2024
Q4 		$219M Sell
32,346,398
-422,788
-1% -$2.84M 1.82% 16
2024
Q3 		$216M Buy
32,769,186
+4,626,268
+16% +$33.2M 1.98% 16
2024
Q2 		$211M Buy
28,142,918
+3,555,357
+14% +$31M 1.87% 17
2024
Q1 		$245M Buy
24,587,561
+3,933,274
+19% +$43.8M 1.7% 16
2023
Q4 		$204M Buy
20,654,287
+13,777,689
+200% +$98.2M 1.21% 24
2023
Q3 		$52.6M Buy
6,876,598
+2,138,081
+45% +$21.3M 0.4% 39
2023
Q2 		$35.4M Buy
4,738,517
+1,161,655
+32% +$8.13M 0.23% 53
2023
Q1 		$23.9M Buy
3,576,862
+477,372
+15% +$3.79M 0.16% 64
2022
Q4 		$23.9M Sell
3,099,490
-260,321
-8% -$2.55M 0.21% 62
2022
Q3 		$35.7M Buy
3,359,811
+627,724
+23% +$6.36M 0.25% 55
2022
Q2 		$16.7M Sell
2,732,087
-95,076
-3% -$636K 0.1% 104
2022
Q1 		$20.2M Buy
2,827,163
+595,150
+27% +$6.33M 0.08% 109
2021
Q4 		$38.2M Sell
2,232,013
-361,823
-14% -$6.81M 0.12% 103
2021
Q3 		$59.7M Buy
2,593,836
+215,161
+9% +$6.1M 0.14% 102
2021
Q2 		$86.8M Buy
+2,378,675
New +$70.4M 0.16% 96

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

ARK Investment Management's RXRX Position: Q2 2026 in Review

ARK Investment Management increased its Recursion Pharmaceuticals (RXRX) stake by 2.8% in Q2 2026, buying an estimated $3.74M and bringing the position to 41,337,632 shares worth $152M. The position accounts for 0.98% of the portfolio, ranked #31.

ARK Investment Management first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $245M in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • ARK Investment Management held 41,337,632 shares of Recursion Pharmaceuticals worth $152M as of Q2 2026.
  • ARK Investment Management bought 1,124,863 Recursion Pharmaceuticals shares in Q2 2026, an estimated $3.74M.
  • Recursion Pharmaceuticals made up 0.98% of ARK Investment Management's portfolio in Q2 2026, its #31 holding.
  • ARK Investment Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • ARK Investment Management's Recursion Pharmaceuticals position peaked at $245M in Q1 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.